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Background
In many countries people die from infectious 
diseases for which effective treatments are known. 
This is often because health services are not 
available or because people 
cannot afford to buy the 
appropriate treatment. 
Many people seek healthcare in 
large unregulated, informal and 
less expensive markets, which 
have emerged to fill access gaps. 
These markets include individuals 
with some basic medical 
knowledge, who sell drugs for a 
living, often antibiotics. 
There is evidence that easy access 
to antibiotics through these 
markets has contributed to falls 
in rates of death from childhood pneumonia and 
infections after childbirth. However, there is also 
evidence of widespread inappropriate use, including 
treatment without a reliable diagnosis or the use of 
partial doses, which may increase the risk of drug 
resistance.
Following increasing calls from a number of 
national governments and global health leaders 
to address the growing challenge of resistance 
to antibiotics, the 68th World Health Assembly 
(WHA) in May 2015 endorsed a global action 
plan to tackle antimicrobial resistance (AMR), 
including antibiotic resistance. The WHA also urged 
all Member States to develop and have in place 
by 2017, national action plans on AMR that are 
aligned with the objectives of the global action plan. 
Whilst a number of governments and international 
agencies are investing in laboratories to undertake 
antibiotic resistance surveillance, 
including the UK through 
its Fleming Fund, much less 
attention has been paid to the 
measures needed to ensure that 
people have access to effective 
treatment for common infections 
and, simultaneously, to reduce 
the risk of the emergence of 
resistant organisms. This is a 
critical dimension that needs to 
be effectively aligned, so that 
AMR does not undermine the 
efforts to achieve universal health 
coverage (UHC).
What changes took place? 
As part of efforts in the Western Pacific to mobilise 
national design and implement action plans, the 
Division of Health Systems in the WHO Regional 
Office for the Western Pacific (WPRO), approached 
the Institute of Development Studies (IDS), a 
Future Health Systems (FHS) partner, to produce a 
background document on integrating concern for 
AMR in UHC strategies for technical discussions 
at the Bi-Regional Technical Consultation on 
Antimicrobial Resistance in Asia and the Tokyo 
Meeting of Health Ministers on Antimicrobial 
Resistance in Asia, both in April 2016. The former 
Integrating actions to tackle 
antimicrobial resistance into 
strategies to achieve universal 
health coverage
It is critical that ensuring people’s access to effective treatment for common infections is 
aligned with efforts to reduce the risk of emerging antimicrobial resistance. The Institute 
of Development Studies, a Future Health Systems partner, is influencing policy agendas to 
give greater focus on the need for the just and sustainable use of antimicrobials. 
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 Antimicrobial 
resistance threatens 
the very core of 
modern medicine and 
the sustainability of an 
effective global public 
health response to the 
enduring threat of 
infectious diseases. 
Margaret Chan, former Director 
General of the WHO, 2015
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was the first time that senior officials from 
Ministries of Health and Agriculture across Asia 
came together to tackle AMR.
The Director of the Division of Health Systems 
at WPRO drew on the background paper for a 
presentation to the Technical Consultation on 
an integrated approach to AMR and UHC. The 
Technical Consultation then informed discussions 
held at the Tokyo Meeting of Health Ministers on 
Antimicrobial Resistance. At the end of the Tokyo 
Meeting, the Communiqué of 
the Tokyo Meeting of Health 
Ministers on Antimicrobial 
Resistance in Asia was issued. 
The latter was influenced by 
the IDS briefing, including its 
emphasis on interdependence 
of drivers of AMR and 
strategies for UHC.
In 2017, the briefing reached 
a wider audience when it was published as a 
chapter in a WHO book and in revised form as 
an article in BMJ Global Health. It is contributing 
to ongoing discussions at the WHO on how to link 
its work on AMR and on UHC.
What FHS evidence and 
learning informed this work?
Work led by IDS has centred on an approach 
that focuses on the need for the just and 
sustainable use of antimicrobials. This means 
ensuring universal access to effective and 
affordable treatment of common infections 
while reducing the risk of the emergence and 
spread of resistance. In many cases, this requires 
formulating strategies for intervening effectively in 
informal markets through which the majority of 
poor people in many countries obtain antibiotics 
to treat infections in both humans and animals.
What next?
Another aspect of the IDS approach is a 
focus on the creation of coalitions for effective 
implementation of national action plans to 
address AMR. IDS is studying local policy 
processes and factors 
influencing actions to improve 
antibiotic use, and engaging 
networks to inform and adopt 
this integrated approach.
IDS has been engaged 
to design and facilitate a 
high level meeting on UHC 
and combating infectious 
diseases in Tokyo in 2018. 
The meeting will be hosted by the Asia-Europe 
Foundation and the Ministry of Foreign Affairs of 
Japan with the objective of mobilising political 
commitment and intersectoral collaboration 
for action to integrate a concern for AMR into 
strategies for accelerating progress towards UHC.
IDS is also involved in several studies on the use 
of antibiotics in animal husbandry. Here too, the 
challenge is to enable farmers to use these drugs 
to improve their efficiency, while limiting the risk 
of resistance. Our findings demonstrate the need 
for a One Health approach, which addresses 
the different pathways for the emergence and 
transmission of organisms resistant to treatment.
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 Ensuring universal 
access to effective and 
affordable treatment of 
common infections 
while reducing the risk 
of the emergence and 
spread of resistance. 
